Skip to main content
Download PDF

AgeWell.de – study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients

BMC Geriatrics volume 19, Article number: 203 (2019) Cite this article

Abstract

Background

In the absence of treatment options, the WHO emphasizes the identification of effective prevention strategies as a key element to counteract the dementia epidemic. Regarding the complex nature of dementia, trials simultaneously targeting multiple risk factors should be particularly effective for prevention. So far, however, only few such multi-component trials have been launched, but yielding promising results. In Germany, comparable initiatives are lacking, and translation of these complex interventions into routine care was not yet done. Therefore, AgeWell.de will be conducted as the first multi-component prevention trial in Germany which is closely linked to the primary care setting.

Methods

AgeWell.de will be designed as a multi-centric, cluster-randomized controlled multi-component prevention trial. Participants will be older community-dwelling general practitioner (GP) patients (60–77 years; n = 1,152) with increased dementia risk according to CAIDE (Cardiovascular Risk Factors, Aging, and Incidence of Dementia) Dementia Risk Score. Recruitment will take place at 5 study sites across Germany. GP practices will be randomized to either intervention A (advanced) or B (basic). GPs will be blinded to their respective group assignment, as will be the statistician conducting the randomization. The multi-component intervention (A) includes nutritional counseling, physical activity, cognitive training, optimization of medication, management of vascular risk factors, social activity, and, if necessary, further specific interventions targeting grief and depression. Intervention B includes general health advice on the intervention components and GP treatment as usual. We hypothesize that over the 2-year follow-up period the intervention group A will benefit significantly from the intervention program in terms of preserved cognitive function/delayed cognitive decline (primary outcome), and other relevant (secondary) outcomes (e.g. quality of life, social activities, depressive symptomatology, cost-effectiveness).

Discussion

AgeWell.de will be the first multi-component trial targeting risk of cognitive decline in older adults in Germany. Compared to previous trials, AgeWell.de covers an even broader set of interventions suggested to be beneficial for the intended outcomes. The findings will add substantial knowledge on modifiable lifestyle factors to prevent or delay cognitive decline.

Trial registration

German Clinical Trials Register (reference number: DRKS00013555).

Peer Review reports

Background

Relevance

Dementia is not only burdensome for the individuals affected and their relatives, it is also a major public health concern [1]. A substantial increase in the absolute number of people affected is to be expected due to dramatic demographic changes [1, 2]. So far, most types of dementia, particularly Alzheimer’s dementia (AD) as the most common type (60–70% of cases; [3]), cannot be cured. Therefore, the identification of effective strategies for prevention has been emphasized as a key element to counteract the dementia epidemic [4, 5].

Numerous vascular and lifestyle factors have been linked to dementia and AD [6, 7], suggesting that 35% of current dementia cases could be attributed to nine modifiable risk factors (midlife hypertension and obesity, diabetes mellitus, depression, physical inactivity, smoking, low educational attainment, hearing loss, and social isolation [8,9,10,11]. Similar results were found for Germany, suggesting a tremendous potential for prevention [10]. Indeed, recent studies indicated trends towards lower dementia incidence in Western high-income countries, likely being the result of improvements in such modifiable lifestyle factors [12]. Further modifiable risk factors may include the use of anticholinergic drugs [13] and atrial fibrillation [14]. Previous randomized controlled trials (RCTs) on interventions aiming at preventing cognitive decline, however, mainly focused on the management of single such risk factors [7]. Regarding the complex nature of dementia as well as the concurrence and interaction of the underlying risk factors, RCTs simultaneously targeting multiple risk factors should be more effective [7]. Large international multi-component trials [15,16,17] yielded very promising results in this regard.

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was the first large RCT providing evidence that a multi-component intervention can be effective in improving or maintaining cognitive functioning in older individuals [5, 16]. Individuals aged 60–77 years (n = 1,200) with an increased dementia risk were randomly assigned to receive either a 2-year multi-component intervention (nutritional counseling, physical activity enhancement, cognitive training, vascular risk monitoring) or regular health advice (control group). The primary outcome was change in cognition as measured through a comprehensive neuropsychological test battery (NTB) [16]. During the 2-year follow-up period, cognition improved significantly in the intervention group compared to the control group [5].

In Germany, comparable initiatives have been lacking so far. Thus, the AgeWell.de study is designed to first-time investigate prevention potential for cognitive decline through a multi-component intervention, with a focus on modifiable risk factors such as, for example, lifestyle interventions, in older primary care patients in Germany.

Objectives

The primary objective of AgeWell.de is to evaluate the effectiveness of a multi-component intervention in preventing or delaying cognitive decline in older adults at increased risk for dementia, specifically tailored to the German health care context. To do so, a pragmatic multi-centric, cluster-randomized controlled prevention trial will be conducted in primary care. The secondary objective is to assess effects of the multi-component intervention regarding (i) mortality, (ii) nursing home placement, (iii) functioning in everyday activities, (iv) quality of life, (v) depressive symptoms, (vi) social inclusion, and (vii) the cost-effectiveness of the intervention. A detailed overview of the study aims and associated hypotheses is provided in Fig. 1.

Fig. 1
figure 1

Study aims and hypotheses of AgeWell.de

Full size image

On the one hand, our study will be guided by the FINGER trial by including the components nutritional counseling, physical activity enhancement, cognitive training, and vascular risk monitoring in the 2-year intervention program. On the other hand, we aim to additionally include components of social lifestyle and recommendations on medication overuse and underuse. Encouraging participants to be socially active should also be a beneficial component of the intervention as even in old age an active lifestyle is protective against dementia [6, 18,19,20]. Likewise, we will provide specific recommendations on the medications of the study participants to their respective GP, if needed. German health claims data suggested that 22–25% of individuals aged 64 years and older receive at least one prescription of a potentially inappropriate medication (PIM) drug within one year [21, 22]. Primary data from a sample of community-dwelling people with dementia indicate that 22% receive at least one PIM with the highest prevalence being antidepressants, benzodiazepines and analgetics [23]. PIM constitutes a major public health concern especially in older age leading, for example, to an increased risk of adverse drug reactions, hospitalization, and mortality [24, 25]. Moreover, PIM is of particular importance as studies strongly suggest that specific drugs (e.g. with anticholinergic properties) can also increase the risk for dementia [13, 26, 27]. On the other hand, medication underuse can modify cardiovascular and other risks [28] and thus outcomes relevant for dementia development.

Finally, we will address further known risk factors for dementia by providing specific interventions in case of bereavement, grief, and depressive symptoms [29, 30], if necessary. The broad range of outcomes will additionally enable the estimation of total benefit and cost-effectiveness of the intervention suggested to be more beneficial for the intended outcomes. The study protocol describes the rationale and the study design of the AgeWell.de trial in adherence to the SPIRIT 2013 statement (Standard Protocol Items: Recommendations for Interventional Trials; [31]).

Methods

Study design

To evaluate the effectiveness of a multi-component intervention in preventing or delaying cognitive decline in older adults at risk, a multi-centric cluster-randomized controlled trial with primary care patients will be conducted (Fig. 2).

Fig. 2
figure 2

AgeWell.de study design

Full size image

Inclusion and exclusion criteria

To target individuals at risk for dementia and suitable for the preventive intervention program, we will include community-dwelling GP patients who are 60–77 years old and have an increased CAIDE Dementia Risk Score (Cardiovascular Risk Factors, Aging, and Incidence of Dementia; [16, 32]). We will use a CAIDE Dementia Risk Score ≥ 9 for inclusion. The risk score predicted dementia risk with a sensitivity of 0.77 and a specificity of 0.63, when a cut-off ≥9 was applied [32]. CAIDE is based on information that is easy to assess (age, education, gender, blood pressure, body mass index, total cholesterol, and physical activity). Therefore, case finding of eligible participants for AgeWell.de can be easily conducted in the GP practices. Moreover, the procedure could be transferred into daily care later on.

Exclusion criteria are conditions affecting safe engagement in the intervention (malignant disease/fatal illness, severe clinical depression, symptomatic cardiovascular disease, revascularization within the previous year) as judged by the GP; severe loss of vision, hearing, or communicative ability/insufficient ability to speak and read German; severe mobility impairment; concurrent participation in another intervention trial, and previously diagnosed dementia or dementia suspected by the GP.

Interventions

During the 2-year follow-up period, participants of intervention group A (advanced) will receive a systematic comprehensive multi-component intervention program (Table 1). All intervention components will be delivered face-to-face by the study nurses during a visit at the participants’ homes. The intervention will include

  • advice on healthy nutrition, based on the guidelines of the German Nutrition Society (DGE)

  • exercises for strength, balance and flexibility on two days per week; aerobic training (3–5 days per week for 20–30 min) planned individually with the participant

  • cognitive training with tablet computers, using the cognitive training software “NeuroNation”, three times per week

  • enhancement of social engagement, planned individually with the participant

  • if necessary, feedback on vascular risk factors (e.g. smoking, medical history) and ways to reduce the respective risk

  • assessment of depressive symptoms and underlying risk factors (e.g. bereavement, grief); if necessary, patients will be encouraged to contact their GP who will provide adequate support and care (e.g. referring participants to groups, psychiatrists, psychotherapists, psychiatric hospitals); written information on addresses and helplines which can be contacted in case of grief and/or depressive symptoms.

  • optimization of medication: see Table 1 for a detailed description.

Table 1 Components of the AgeWell.de intervention program (intervention group A)
Full size table

Participants of intervention group B (basic) will receive GP treatment as usual (GPTAU) and general health advice (GHA) related to the components of intervention A. We hypothesize that the multi-component intervention program of intervention A will be superior to GPTAU and GHA (intervention B) regarding trial outcomes.

Outcomes

Primary endpoint

In accordance with previous trials [2, 5, 7], we will assess change in cognitive performance as the primary endpoint. Cognitive performance will be assessed with a neuropsychological test battery covering the six cognitive domains for diagnosing mild and/or major neurocognitive disorder according to DSM-5 (attention, executive function, learning/memory, language, perceptual-motor abilities, and social cognition). Composite cognitive z-scores based on the results from all single tests will be calculated. Single z-scores will be calculated using baseline mean and standard deviations and then, for the composite score, the single z-scores will be averaged.

Secondary endpoints

An overview of secondary endpoints (mortality, nursing home placement, instrumental activities of daily living/activities of daily living, quality of life, depressive symptoms, social inclusion, motivation for behavior change, cost-effectiveness) is provided in Fig. 1. Corresponding assessments are detailed in Table 2. Furthermore, we will assess readiness for behavior change and explore mediating and moderating factors for the effectiveness of the intervention.

Table 2 Instruments used in AgeWell.de
Full size table

Sample size

Sample size calculations are based on a composite z-score of cognitive performance from previous findings in mild AD [61], i.e., a mean decrease in the composite z-score of cognitive performance of − 0.21 with a common SD of 0.5 is assumed in intervention group B during the two year follow-up period. Accordingly, the required sample size is estimated to be 475 participants per group in order to detect a 50% difference in change in the composite z-score between intervention groups (2-sided t-test for equal variances; with 5% significance level and 90% power). We assume an inflation factor of 1.1 (corresponding to an intra-cluster correlation coefficient of 0.02 and a cluster size of 6). In view of the findings from the FINGER trial, we further assume a dropout rate of no higher than 10% [5]. Therefore, a total sample size of n = 1,152 individuals (n = 576 per group) seems sufficient.

Recruitment procedure

To ensure the inclusion of 1,152 patients, recruitment will take place at five study sites across Germany (Greifswald, Kiel, Leipzig, and Munich/Halle; Fig. 3). We estimate that (i) 30% of the GP patients between 60 and 77 years are eligible for the study (according to the FINGER trial, approximately 40% have the required CAIDE Dementia Risk Score ≥ 9 [30]; among these another 25% are estimated to be excluded according to the AgeWell.de exclusion criteria.). Based on previous experiences from other multi-centric trials [62, 63] and regarding the demanding nature of this prevention trial, we assume a rather conservative response rate of approximately 33%. Thus, every study site will screen n = 2,880 GP patients to identify n = 864 potentially eligible GP patients (except for Munich/Halle: half numbers due to shared recruitment between the two study sites). To ensure these numbers, we suggest a number of n = 24 GP practices per study site (n = 96 GP practices in total) as sufficient, leading to a total number of n = 12 patients that have to be recruited per GP practice. GP practices will receive monetary incentives for recruitment and provision of patients’ data.

Fig. 3
figure 3

AgeWell.de recruitment of participants per study site

Full size image

Randomization

To ensure a balance in sample size across groups over time, block-randomization of the GP practices will be used with a targeted assignment ratio of participants to intervention A vs. B of 1:1. Participating GP practices (clusters) will be randomized either to intervention A or B. Randomization will be conducted at the data management center at the Institute for General Practice at the Hannover Medical School, using a randomization list that is concealed to the recruiting study sites.

Blinding

Whereas blinding of interviewers and study nurses cannot be realized in AgeWell.de, GPs will be blinded towards their respective group allocation. Eligible participants will receive all necessary information about the study in an information sheet provided by the GP, including information on the components of both interventions and on the random assignment of participants to either intervention A or B. After signing an informed consent at the GP’s practice, participants will receive a letter from the study sites with information on their respective group allocation and on next steps of the study.

Data collection

Each study center will be recruiting GP practices using an invitation letter with information on study design and aims as well as GPs’ duties during the trial. GPs interested in study participation can reply per fax or telephone. The recruiting study sites will then schedule a personal appointment at the GP practice to explain the recruitment procedure and to provide all necessary documents (informed consent form, patient information, screening sheets etc.).

Case finding and recruitment will be conducted by the GP practices. Data of regular GP patients will be screened by trained practice personnel in association with the AgeWell.de-study personnel, according to the inclusion and exclusion criteria. The GP will then provide all necessary information about the study to eligible patients. Patients who are interested in study participation will sign an informed consent. Contact information of the patients will be sent to the local recruiting centers. Next, patients who have consented to participate will receive a letter from the study personnel, informing them about their respective group allocation. Home visits for baseline assessment will be scheduled.

At baseline and at follow-up assessment after 24 months, fully structured interviews will be conducted with all participants, assessing the primary and secondary endpoints. Other relevant information assessed include sociodemographic information, subjective cognitive decline, self-reported impairments and symptoms, anthropometry, blood pressure, nutrition, physical activity, bereavement/grief, medication, vascular risks). Moreover, GPs will provide data on participants’ health characteristics (diagnoses, lab values, medication) using standardized questionnaires. To conduct the process evaluation, the success rate of recruitment (number of eligible GP patients, number of participants and non-participants, (baseline) characteristics of participants and non-participants, reasons for non-participation) will be provided by the GP practice personnel. Standardized telephone interviews on reasons for dropout will be held with intervention A-participants, if applicable. For participants in intervention A, additional interim sessions will be scheduled: one face-to-face assessment after 12 months at the participants’ home and five telephone calls after 2, 4, 8, 16, and 20 months, respectively (see Table 3). These fully structured interviews serve the purpose of monitoring adherence to the intervention and motivation (monitoring & booster sessions). Participants in intervention group A will be asked to track their activities in the intervention components using weekly diaries. To reduce non-response as well as dropout in AgeWell.de, interviewers will undergo training regarding all procedures and assessments, including motivational interviewing techniques [64]. Likewise, motivational tasks will also be carried out by the principal investigators (Table 1).

Table 3 Schedule of enrolment, interventions and assessments in the course of AgeWell.de
Full size table

Data management

Each local recruiting center will enter collected data via an internet-based electronic data capture system which complies with the FDA requirements (21 CFR Part 11) as well as the guidelines for Good Clinical Practice (GCP). Data will be stored in a central Oracle-database. For statistical analyses, data can be exported via a web-based export-tool into SPSS, SAS, CDISC ODM, or similar.

The technical infrastructure includes the internet-based remote data entry system and the central database server. Data will not be stored locally. For transfers, data will be secured using 128 bit SSL encryption. Access to the database and webserver is controlled by two consecutive firewall systems. Data will only be stored using a pseudonym generated automatically upon first entry of a patient’s data into the database. Access to the electronic data entry system will be provided to members of the AgeWell.de study group according to a detailed concept of roles and rights.

Statistical analyses

Preliminary analyses involve three parts. First, data will be cleaned and checked for inconsistencies by statisticians at the central data management center to ensure data accuracy and coherence. Second, outcome variables will be examined to identify potential outliers and leverage points. Third, missing data will be inspected and handled according to patterns of data missingness, e.g., by multiple imputation [65].

A dropout analysis will be performed to test whether complete and incomplete cases differ according to relevant sociodemographic variables, potentially introducing selection bias.

Descriptive analyses will be carried out to examine differences in baseline measurements regarding the composite cognitive z-score (primary endpoint) and secondary endpoints between the two intervention groups. Additionally, single scores for the six neurocognitive domains will be calculated and analyzed. Suitable balancing techniques, such as entropy balancing, will be used for baseline measurements to warrant a high degree of comparability between study groups [66]. In order to analyze changes in primary and secondary endpoints of the two groups over time (treatment effect), latent growth curve modeling (LGM) will be utilized. Group membership (A vs. B) as well as other time-invariant characteristics will be assessed as predictors of change in cognitive performance in the models. Model estimates will be weighted using, for example, calculated entropy balancing weights to equalize possible baseline differences in covariates and outcomes. The models will further be stratified by age and gender to evaluate whether treatment effects on primary and secondary outcomes differ by subgroups.

Secondary analyses include, among others, investigation of effects of drug-associated risk factors. Effects of the intervention in patients with or without such factors will be analyzed by comparing primary and secondary endpoints in the respective subgroups. Plans for stratified analyses by overall cognitive performance as expressed by MoCA scores are effective. Cost-effectiveness will be analyzed based on both direct costs and quality-adjusted life-years (QALYs). To derive direct costs, health care utilization during 24 months follow-up will be valued using specific German unit costs. Intervention costs will be calculated using accounting principles. QALYs will be calculated using preference-based utilities as derived from the EQ-5D-5 L. Additionally, incremental cost-effectiveness ratios (ICER) will be calculated and net benefit regressions will be conducted to determine the uncertainty of the point estimates of the ICER [67].

Monitoring

Data monitoring

A data monitoring committee will not be established as the overall risk associated with the trial is considered low, and therefore, the likelihood for the need to modify or discontinue the trial is considered insignificant. However, precautions have been taken to minimize the potential of any harms, as detailed below. Moreover, a detailed process evaluation will be conducted throughout the entire trial to produce in-depth insight into the delivery of the interventions, (i) to prevent drawing inappropriate conclusions on the efficacy or effectiveness of the interventions, and (ii) to formulate recommendations for future studies [68]. Most importantly, process evaluation should be used to identify and avoid potential burdens for study participants and GPs. The process evaluation will comprise three dimensions:

  1. 1)

    Evaluation of the success rate of recruitment: Standardized questionnaires filled in by the GP personnel collecting number of eligible patients, number of participants and non-participants, baseline-characteristics of both groups, and reasons for non-participation. Loss of participants during the follow-up-period as well as reasons for leaving the study will be assessed to evaluate attrition rate as well as barriers and facilitators for staying in the trial [5].

  2. 2)

    Evaluation of the quality of the execution of the intervention components: At every face-to-face or telephone interim session, adherence to the intervention will be assessed using standardized questionnaires with intervention A participants in order to identify potential barriers and facilitators for adherence to the intervention. Likewise, GPs will be asked to fill out a standardized questionnaire to identify potential burdens for participating GPs.

  3. 3)

    Evaluation of the process of data acquisition regarding completeness and validity: Documentation of reasons for discontinuing an assessment before completion as well as the motivation of the participants and the GPs for assessment. Number and characteristics of missing data will be analyzed. Information will be used to evaluate barriers and facilitators for data collection.

Harms

Trial-related adverse events (AEs) will be assessed without regard towards a causal relation to the intervention. AEs will be recorded at each contact with participants after the baseline assessment. AEs in AgeWell.de include loss experiences and grief, depressive symptoms, severe injuries, hospitalization, and private or occupational stress reported by participants. Specific AEs (depressive symptoms; severe injuries; hospitalization) will be considered serious adverse events (SAEs) if they result in a life-threatening condition (immediate risk or death), hospitalization/prolongation thereof, or any lasting impairment. Occurrence of AEs/SAEs will be documented in the electronic database after each contact with participants. In case of a SAE, an automatic case-report form will notify the coordinating study center at the University of Leipzig, which, in turn, will contact the respective study center. A shared decision will then be made between the coordinating study center and non-elective principal investigator (PI) at the respective study center, including one of the following options: informing the participants’ GP about the SAE, interruption or discontinuation of trial participation, or none of the above.

Auditing

Auditing will take place in form of reviews of the data collection across key assessment waves for each recruitment center. Specifically, 2 % of the questionnaires at baseline, at the face-to-face interim assessment (for intervention group A only), and at follow-up, respectively, will be randomly drawn and inspected regarding their degree of matching with the database input. Source data verification will be performed independently from investigators by the Hannover Medical School that is the entrusted site performing all data management tasks throughout the whole trial.

Protocol amendments

Possible modifications to the protocol will be tracked in the German Clinical Trials Register (DRKS, registry number: DRKS00013555).

Dissemination policy

AgeWell.de results will be published in scientific international, peer-reviewed journals, if possible with open access. Moreover, results will be presented at national and international scientific conferences as well as during seminars for GPs, regional care networks, and public events for seniors. Furthermore, publication results will be disseminated to the wider research community via press releases.

Organizational structure and responsibilities

The Institute for Social Medicine, Occupational Health and Public Health (ISAP) in Leipzig acts as the coordinating center in AgeWell.de. This implies the organization of regular telephone-conferences and meetings with all participating centers, the compensation of all participating GP practices, preparation of documents needed for the conduct of the trial as well as reports to the funder of the study. Moreover, the study center in Leipzig also acts as one of the recruiting centers. As a subcontractor, the Institute for General Practice at the Hannover Medical School acts as the responsible study site for the task of data management, including the setup of the internet-based remote data capture system. The study centers in Greifswald, Kiel and Munich/Halle act as further recruiting study sites. Evaluation of cost-effectiveness of the trial will be conducted by the Department of Health Economics and Health Service Research at the University Medical Center Hamburg-Eppendorf. The intervention component “optimization of medication” will be realized by the Department of Clinical Pharmacology and Pharmacoepidemiology at the University Hospital Heidelberg, including the programming of algorithms to evaluate electronic data for optimization of medication and provision of documents for corresponding feedback to and from the GP.

Discussion

Multi-domain interventions targeting lifestyle factors have been pointed out as a promising prevention strategy against dementia in international trials [5]. AgeWell.de will be the first such multi-component trial in older adults in Germany. We hypothesize that the multi-component intervention will be superior to general health advice and GPTAU in maintaining cognitive functioning in older adults at risk for dementia (primary hypothesis). Moreover, we assume beneficial effects in reducing mortality, nursing home placement, depressive symptoms, and in maintaining quality of life as well as functioning in everyday life (secondary hypotheses). Subsequently, this should also reduce direct health costs.

The AgeWell.de-study will add valuable insights regarding the role of modifiable risk and lifestyle factors to prevent or delay cognitive decline. A specifically useful asset should be findings from the intervention components that address potentially inappropriate medication [13, 26] and depression [8, 9, 69], which, to our knowledge, have not been examined in comparable RCTs so far.

Beyond that, our intervention will possibly also reduce risk for other diseases such as hypertension, stroke, cardiovascular disease, overweight etc. by addressing common risk factors for the respective diseases [2].

Limitations

Participation in our prevention trial is rather demanding since the intervention components address various lifestyle factors and require e.g. cognitive training and physical activity on several days a week. The follow-up period is longer than in most previous trials testing single interventions. Therefore, adherence to the intervention might be lower compared to trials targeting only single components for a shorter time period. These factors also raise the chance of dropping out. We will address these potential problems by putting a strong focus on continuous motivation of participants and monitoring of adherence to the intervention, e.g. by regular telephone contacts and the use of motivational interviewing techniques. For ethical reasons, general health advice and feedback on known risk factors for dementia will also be provided to intervention group B. On these grounds, estimates of the effects of our intervention should be considered to be conservative.

Outlook

Since the domains of our multi-component intervention address behaviors common in the general population, the intervention, if effective, will be implemented in real world settings. Thereby, AgeWell.de could add to targeted and cost-effective strategies in preventing dementia in older adults at risk. Most interventions tested (e.g. physical activity and a wholesome diet) are easily available to the majority of older adults [70]. Likewise, AgeWell.de addresses lifestyle factors that are common in general practice. Therefore, even a moderate decrease in exposure to the targeted lifestyle factors could lead to a significant reduction in incident dementia cases on a population level [5, 70]. Concerning the projected increase in number of dementia cases due to ageing populations, there is an evident need for effective prevention strategies. This becomes particularly relevant in regard to the absence of effective treatment options. To date, lifestyle interventions might constitute the most cost-effective and sustainable option for dementia prevention [71]. Against this background, the results of AgeWell.de will make a highly relevant contribution to the growing body of knowledge on modifiable risk factors for dementia.

Availability of data and materials

After publication of the final AgeWell.de trial results, electronic research data will be made accessible free of charge for third parties/further interested researchers upon request from the central data management center (work group Medical Statistics and IT-infrastructure at the Institute for General Practice, Hannover Medical School).

Abbreviations

AD:

Alzheimer’s disease

ADL:

Activities of daily living

AE:

Adverse event

BMBF:

Bundesministerium für Bildung und Forschung (German Federal Ministry for Education and Research)

CAIDE score:

“Cardiovascular Risk Factors, Aging, and Incidence of Dementia” Dementia Risk Score

CERAD:

Consortium to Establish a Registry for Alzheimer’s Disease

DSM-5:

Diagnostic and statistical manual of mental disorders, 5th edition

FINGER:

Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability

GCP:

Good clinical practice

GHA:

General health advice

GP:

General practitioner

GPTAU:

General practitioner treatment as usual

IADL:

Instrumental activities of daily living

ICER:

Incremental cost-effectiveness ratios

LGM:

Latent growth curve modeling

MoCA:

Montreal Cognitive Assessment

NTB:

Neuropsychological test battery

PI:

Principal investigator

PIM:

Potentially inappropriate medication

RCT:

Randomized controlled trial

SAE:

Serious adverse event

SD:

Standard deviation

References

  1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer's Disease International (ADI); 2015.

  2. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease. Lessons learned from clinical trials and future directions. Lancet Neurol. 2015;14:926–44.

    Article  Google Scholar 

  3. World Health Organization. Fact sheet N 362: dementia. Geneva: WHO Press; 2015.

    Google Scholar 

  4. World Health Organization. Dementia: a public health priority. Geneva: World Health Organization; 2012

  5. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). A randomised controlled trial. Lancet. 2015;385:2255–63.

    Article  Google Scholar 

  6. Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current epidemiological evidence and future perspective. Alzheimers Res Ther. 2012;4:6.

    Article  Google Scholar 

  7. Sindi S, Mangialasche F, Kivipelto M. Advances in the prevention of Alzheimer's Disease. F1000prime Rep. 2015;7:50.

    Article  Google Scholar 

  8. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819–28.

    Article  Google Scholar 

  9. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94.

    Article  Google Scholar 

  10. Luck T, Riedel-Heller SG. Prävention von Alzheimer-Demenz in Deutschland. Eine Hochrechnung des möglichen Potenzials der Reduktion ausgewählter Risikofaktoren. Nervenarzt. 2016;87:1194–200.

    Article  CAS  Google Scholar 

  11. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care. Lancet. 2017;390:2673–734.

    Article  Google Scholar 

  12. Roehr S, Pabst A, Luck T, Riedel-Heller SG. Is dementia incidence declining in high-income countries? A systematic review and meta-analysis. Clin Epidemiol. 2018;10:1233.

    Article  Google Scholar 

  13. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7.

    Article  Google Scholar 

  14. Jacobs V, Cutler MJ, Day JD, Bunch TJ. Atrial fibrillation and dementia. Trends Cardiovasc Med. 2015;25:44–51.

    Article  Google Scholar 

  15. Richard E, van den Heuvel E, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, van Gool WA. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009;23:198–204.

    Article  Google Scholar 

  16. Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Nissinen A, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H. The Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimers Dement. 2013;9:657–65.

    Article  Google Scholar 

  17. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, Cuffi MN, Bordes S, Gasnier Y, Robert P. MAPT study: a multidomain approach for preventing Alzheimer’s disease: design and baseline data. J Prev Alzheimers Dis. 2014;1:13.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Karp A, Paillard-Borg S, Wang H, Silverstein M, Winblad B, Fratiglioni L. Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dement Geriatr Cogn Disord. 2006;21:65–73.

    Article  Google Scholar 

  19. Paillard-Borg S, Fratiglioni L, Winblad B, Wang H. Leisure activities in late life in relation to dementia risk: principal component analysis. Dement Geriatr Cogn Disord. 2009;28:136–44.

    Article  Google Scholar 

  20. Paillard-Borg S, Fratiglioni L, Xu W, Winblad B, Wang H. An active lifestyle postpones dementia onset by more than one year in very old adults. J Alzheimers Dis. 2012;31:835–42.

    Article  Google Scholar 

  21. Amann U, Schmedt N, Garbe E. Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS list. Dtsch Arztebl Int. 2012;109:69.

    PubMed  PubMed Central  Google Scholar 

  22. Schubert I, Küpper-Nybelen J, Ihle P, Thürmann P. Prescribing potentially inappropriate medication (PIM) in Germany's elderly as indicated by the PRISCUS list. An analysis based on regional claims data. Pharmacoepidemiol Drug Saf. 2013;22:719–27.

    Article  Google Scholar 

  23. Wucherer D, Eichler T, Hertel J, Kilimann I, Richter S, Michalowsky B, Thyrian JR, Teipel S, Hoffmann W. Potentially inappropriate medication in community-dwelling primary care patients who were screened positive for dementia. J Alzheimers Dis. 2017;55:691–701.

    Article  Google Scholar 

  24. Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74.

    Article  Google Scholar 

  25. Dormann H, Sonst A, Müller F, Vogler R, Patapovas A, Pfistermeister B, Plank-Kiegele B, Kirchner M, Hartmann N, Bürkle T. Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int. 2013;110:213.

    PubMed  PubMed Central  Google Scholar 

  26. Jessen F, Kaduszkiewicz H, Daerr M, Bickel H, Pentzek M, Riedel-Heller S, Wagner M, Weyerer S, Wiese B, van den Bussche H. Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur Arch Psychiatry Clin Neurosci. 2010;260:111–5.

    Article  Google Scholar 

  27. Heser K, Luck T, Röhr S, Wiese B, Kaduszkiewicz H, Oey A, Bickel H, Mösch E, Weyerer S, Werle J, Brettschneider C, König H, Fuchs A, Pentzek M, van den Bussche H, Scherer M, Maier W, Riedel-Heller SG, Wagner M. Potentially inappropriate medication: association between the use of antidepressant drugs and the subsequent risk for dementia. J Affect Disord. 2018;226:28–35.

    Article  Google Scholar 

  28. Meid AD, Groll A, Heider D, Mächler S, Adler J, Günster C, König H, Haefeli WE. Prediction of drug-related risks using clinical context information in longitudinal claims data. Value Health. 2018;21:1390–8.

    Article  Google Scholar 

  29. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer report 2014: dementia and risk reduction: an analysis of protective and modifiable risk factors. London: Alzheimer Disease International; 2014.

    Google Scholar 

  30. Sikorski C, Luppa M, Heser K, Ernst A, Lange C, Werle J, Bickel H, Mösch E, Wiese B, Prokein J. The role of spousal loss in the development of depressive symptoms in the elderly—implications for diagnostic systems. J Affect Disord. 2014;161:97–103.

    Article  Google Scholar 

  31. Moher D, Chan A. SPIRIT (standard protocol items: recommendations for interventional trials), Guidelines for Reporting Health Research: A User's Manual; 2014. p. 56–67.

    Google Scholar 

  32. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735–41.

    Article  Google Scholar 

  33. German Nutrition Society: 10 guidelines of the German Nutrition Society (DGE) for a wholesome diet. [https://www.dge.de/fileadmin/public/doc/fm/10-guidelines-for-a-wholesome-diet.pdf]. Accessed 17 Nov 2018.

  34. O'mahony D, O'sullivan D, Byrne S, O'connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.

    Article  Google Scholar 

  35. Reitan RM. Trail Making Test: Manual for administration and scoring. Tempe, AZ: Reitan neuropsychology laboratory; 1992

  36. Satzger W, Hampel H, Padberg F, Bürger K, Nolde T, Ingrassia G, Engel RR. Practical application of the CERAD test battery as a neuropsychological dementia screening test. Nervenarzt. 2001;72:196–203.

    Article  CAS  Google Scholar 

  37. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull. 1988;24:641–52.

    CAS  PubMed  Google Scholar 

  38. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The consortium to establish a registry for Alzheimer's disease (CERAD): I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-65.

    Article  Google Scholar 

  39. Isaacs B, Kennie AT. The set test as an aid to the detection of dementia in old people. Br J Psychiatry. 1973;123:467–70.

    Article  CAS  Google Scholar 

  40. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999;14:167–77.

    CAS  PubMed  Google Scholar 

  41. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356–64.

  42. Bölte S. Reading Mind in the Eyes Test für Erwachsene (dt. Fassung) von S, Baron-Cohen [Reading the mind in the eyes test for adults (German version) by S. Baron-Cohen]. Frankfurt: JW Goethe Universität Frankfurt/M; 2005.

    Google Scholar 

  43. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The “Reading the mind in the eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry Allied Discip. 2001;42:241–51.

    Article  CAS  Google Scholar 

  44. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.

    Article  Google Scholar 

  45. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index: a simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill. Maryland state medical journal. 1965;14:56–61.

  46. Am Sikkes S, Knol DL, Pijnenburg YAL, De Lange-de Klerk, Elly SM, Uitdehaag BMJ, Scheltens P: Validation of the Amsterdam IADL Questionnaire©, a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology 2013, 41:35-41.

    Article  Google Scholar 

  47. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199.

    Article  Google Scholar 

  48. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13:299–310.

    Article  CAS  Google Scholar 

  49. Winkler I, Matschinger H, Angermeyer MC. Der WHOQOL-OLD -- Ein Fragebogen zur interkulturellen Erfassung der Lebensqualität im Alter. Psychother Psychosom Med Psychol. 2006;56:63–9.

    Article  Google Scholar 

  50. Gauggel S, Birkner B. Validity and reliability of a German version of the geriatric depression scale (GDS). Zeitschrift fur Klinische Psychologie-Forschung und Praxis. 1999;28:18–27.

    Article  Google Scholar 

  51. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. The Journal of Aging and Mental Health. 1986;5(1-2):165–173.

  52. Lubben J, Blozik E, Gillmann G, Iliffe S, von Renteln Kruse W, Beck JC, Stuck AE. Performance of an abbreviated version of the Lubben social network scale among three European community-dwelling older adult populations. Gerontologist. 2006;46:503–13.

    Article  Google Scholar 

  53. Seidl H, Bowles D, Bock J, Brettschneider C, Greiner W, König H, Holle R. FIMA–Fragebogen zur Erhebung von Gesundheitsleistungen im Alter: Entwicklung und Pilotstudie. Das Gesundheitswesen. 2015;77:46–52.

    CAS  PubMed  Google Scholar 

  54. Bock J, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, König HH. Ermittlung standardisierter Bewertungssätze aus gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. Das Gesundheitswesen. 2015;77:53–61.

    PubMed  Google Scholar 

  55. Schwarzer R, Renner B. Health-specific self-efficacy scales. Freie Universität Berlin. 2009;14:2009.

    Google Scholar 

  56. Lippke S, Fleig L, Pomp S, Schwarzer R. Validity of a stage algorithm for physical activity in participants recruited from orthopedic and cardiac rehabilitation clinics. Rehabil Psychol. 2010;55:398.

    Article  Google Scholar 

  57. Jerusalem M, Schwarzer R. Skala zur allgemeinen Selbstwirksamkeitserwartung. In: Skalen zur Erfassung von Lehrer-und Schülermerkmalen. Dokumentation der psychometrischen Verfahren im Rahmen der Wissenschaftlichen Begleitung des Modellversuchs Selbstwirksame Schulen. Berlin: Freie Universität Berlin; 1999.

    Google Scholar 

  58. Rami L, Mollica MA, García-Sanchez C, Saldaña J, Sanchez B, Sala I, Valls-Pedret C, Castellví M, Olives J, Molinuevo JL. The subjective cognitive decline questionnaire (SCD-Q): a validation study. J Alzheimers Dis. 2014;41:453–66.

    Article  Google Scholar 

  59. Haftenberger M, Heuer T, Heidemann C, Kube F, Krems C, Mensink GBM. Relative validation of a food frequency questionnaire for national health and nutrition monitoring. Nutr J. 2010;9:36.

    Article  Google Scholar 

  60. Forstmeier S, Maercker A. Comparison of two diagnostic systems for complicated grief. J Affect Disord. 2007;99:203–11.

    Article  Google Scholar 

  61. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64:1323–9.

    Article  Google Scholar 

  62. Schwarzbach M, Luppa M, Hansen H, König H, Gensichen J, Petersen JJ, Schön G, Wiese B, Weyerer S, Bickel H. A comparison of GP and GDS diagnosis of depression in late life among multimorbid patients–results of the MultiCare study. J Affect Disord. 2014;168:276–83.

    Article  Google Scholar 

  63. Luck T, Riedel-Heller SG, Kaduszkiewicz H, Bickel H, Jessen F, Pentzek M, Wiese B, Koelsch H, van den Bussche H, Abholz H. Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe). Dement Geriatr Cogn Disord. 2007;24:307–16.

    Article  Google Scholar 

  64. Miller WR, Rollnick S. Motivational interviewing: Helping people change. New York: Guilford press; 2012.

  65. van Buuren S. Flexible imputation of missing data. Boca Raton, FL: Chapman and Hall/CRC press; 2012.

  66. Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20:25–46.

    Article  Google Scholar 

  67. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377–401.

    Article  Google Scholar 

  68. Prick A, de Lange J, van’t Leven N, Pot AM. Process evaluation of a multicomponent dyadic intervention study with exercise and support for people with dementia and their family caregivers. Trials. 2014;15:401.

    Article  Google Scholar 

  69. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329–35.

    Article  Google Scholar 

  70. Vellas B, Carrie I, Guyonnet S, Touchon J, Dantoine T, Dartigues J, Cufi MN, Bordes S, Gasnier Y, Robert P, Bories L, Rouaud O, Desclaux F, Sudres K, Bonnefoy M, Pesce A, Fougere B, Delrieu J, Faisant C, Lala F, Dupuy C, Cantet C, Coley N, Belleville S, Willis SL, Weiner MW, Ousset PJ, Andrieu S. MAPT (multi-domain Alzheimer’s prevention trial). Results at 36 months. Alzheimers Dement. 2015;11:P331.

    Article  Google Scholar 

  71. Hussenoeder FS, Riedel-Heller SG. Primary prevention of dementia: from modifiable risk factors to a public brain health agenda? Soc Psychiatry Psychiatr Epidemiol. 2018;53:1289–301.

    Article  Google Scholar 

Download references

Acknowledgements

Members of the AgeWell.de-study group: Principal Investigator: Steffi G. Riedel-Heller; Co-Principal Investigators: Wolfgang Hoffmann, Jochen Gensichen, Walter E. Haefeli, Hanna Kaduszkiewicz, Hans-Helmut König, Thomas Frese, Jochen René Thyrian and David Czock; Franziska Berg, Andrea Bischhoff, Christian Brettschneider, Juliane Döhring, Alexander Eßer, Corinna Gräble, Caroline Jung-Sievers, Kerstin Klauer-Tiedtke, Kerstin Krebs-Hein, Dagmar Lochmann, Tobias Luck, Silke Mamone, Andreas Meid, Michael Metzner, Lydia Neubert, Anke Oey, Susanne Röhr, Franziska Samos, Karin Schumacher, Theresa Terstegen, Sandy Thieme, Lars Wamsiedler, Tanja Wehran, Birgitt Wiese, Ines Winkler, Andrea Zülke, Ina Zwingmann.

Further, the authors want to thank all participating GP-practices and study participants of the AgeWell.de-trial in advance.

We acknowledge support from the German Research Foundation (DFG) and the University Leipzig within the program of Open Access Publishing.

Funding

AgeWell.de is funded by the German Federal Ministry for Education and Research (BMBF; reference numbers: 01GL1704A, 01GL1704B, 01GL1704C, 01GL1704D, 01GL1704E, 01GL1704F). The BMBF had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

Author information

Author notes

  1. Andrea Zülke, Tobias Luck, Susanne Röhr and Steffi G. Riedel-Heller contributed equally to this work.

  2. Susanne Röhr and Steffi G. Riedel-Heller shared last authorship

Authors and Affiliations

  1. Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Philipp-Rosenthal-Strasse 55, 04103, Leipzig, Germany

    Andrea Zülke, Tobias Luck, Alexander Pabst, Susanne Röhr & Steffi G. Riedel-Heller

  2. Department of Economic & Social Sciences & Institute of Social Medicine, Rehabilitation Sciences and Healthcare Research (ISRV), University of Applied Sciences Nordhausen, Nordhausen, Germany

    Tobias Luck

  3. Institute for Community Medicine, University Medicine Greifswald (UMG), Greifswald, Germany

    Wolfgang Hoffmann

  4. German Center for Neurodegenerative Diseases (DZNE), site Rostock/ Greifswald, Greifswald, Germany

    Wolfgang Hoffmann & Jochen René Thyrian

  5. Institute of General Practice/Family Medicine, University Hospital of LMU Munich, Munich, Germany

    Jochen Gensichen

  6. Institute of General Practice, University of Kiel, Kiel, Germany

    Hanna Kaduszkiewicz

  7. Department of Health Economics and Health Service Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Hans-Helmut König

  8. Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany

    Walter E. Haefeli & David Czock

  9. Institute for General Practice, Work Group Medical Statistics and IT-Infrastructure, Hannover Medical School, Hannover, Germany

    Birgitt Wiese

  10. Institute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany

    Thomas Frese

Authors
  1. Andrea Zülke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias Luck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Pabst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfgang Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jochen René Thyrian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jochen Gensichen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hanna Kaduszkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hans-Helmut König
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Walter E. Haefeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David Czock
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Birgitt Wiese
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Thomas Frese
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Susanne Röhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Steffi G. Riedel-Heller
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SRH conceptualized and designed the study and was supported by TL, WH, JRT, JG, HK, HHK, WEH, DC, AP and BW. AZ, TL, SR and SRH drafted the manuscript. WH, JRT, JG, HK, HHK, WEH, DC, BW, AP and TF revised the manuscript for intellectual content. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Andrea Zülke.

Ethics declarations

Ethics approval and consent to participate

AgeWell.de was approved by the responsible ethics boards of all participating study sites (Ethical Committee at the Medical Faculty, Leipzig University; Ethical Committee at the Medical Faculty, Christian-Albrechts-University, Kiel; Ethical Committee at Universitätsmedizin Greifswald; Ethical Committee at the Medical Faculty, Ludwig-Maximilian-University, Munich; Ethical Committee at the Medical Faculty, Martin-Luther-University Halle-Wittenberg; Ruprecht-Karls-University, Heidelberg). The study design was discussed with GPs and seniors organized in a senior interest group (Seniorenbeirat der Stadt Leipzig).

Written consent to participate will be obtained at the GP practice after the GP has provided all necessary information about the study. The signed informed consent form will be sent to the recruiting study site by the GP, along with participants’ contact information and data on participants’ health characteristics. Participants will then be contacted by the recruiting study center, informing them about the next steps of the study.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zülke, A., Luck, T., Pabst, A. et al. AgeWell.de – study protocol of a pragmatic multi-center cluster-randomized controlled prevention trial against cognitive decline in older primary care patients. BMC Geriatr 19, 203 (2019). https://doi.org/10.1186/s12877-019-1212-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12877-019-1212-1

Keywords

BMC Geriatrics

ISSN: 1471-2318

Contact us